NewsOur news NewsBioVersys and GSK successfully complete IMI2 programme reaching clinical MilestoneNewsBioversys AG and Helmholtz Centre for infection research join forces to accelerate AMR research and developmentNewsBioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosisNewsBIOVERSYS APPOINTS NEW CHIEF FINANCIAL OFFICERNewsBioVersys announces first patient dosed in Phase 2 clinical trial with BV100NewsBioVersys announces first patient dosed in Phase 2a clinical trial with BVL-GSK098NewsBioVersys extends its series C round to CHF 32.6 Million with investment from the AMR Action FundBioVersys in the NewsBioVersys for new antibiotic treatmentsBioVersys in the NewsKampf gegen Antibiotikaresistenzen: Die stille Pandemie 123…56Next »
NewsBioversys AG and Helmholtz Centre for infection research join forces to accelerate AMR research and development
NewsBioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosis
NewsBioVersys extends its series C round to CHF 32.6 Million with investment from the AMR Action Fund